Latest news with #MorehouseSchoolofMedicine
Business Wire
27-05-2025
- Health
- Business Wire
BeeKeeperAI Enables Icahn School of Medicine at Mount Sinai and Morehouse School of Medicine to Test the Performance of Healthcare AI Models in Their Environments
AUSTIN, Texas--(BUSINESS WIRE)--BeeKeeperAI®, Inc., a pioneer in privacy-enhancing, multi-party collaboration software for AI development and deployment, today announced that Morehouse School of Medicine (MSM) and the Icahn School of Medicine at Mount Sinai will utilize BeeKeeperAI's EscrowAI® platform to rapidly test AI models on their real-world, multi-modal data in chronic heart failure (CHF). This milestone represents the first operational deployment certified under the Coalition for Health AI (CHAI)'s assurance service provider certification process, setting a precedent for how AI models can be responsibly tested and brought to market faster across institutions and populations. 'As we advance our mission to enable responsible, evidence-based AI, this is just the first of many collaborations where CHAI-certified service providers and health institutions will work together to ensure AI serves all patients,' said Dr. Brian Anderson, CEO of CHAI. 'We're proud to see Morehouse School of Medicine, Icahn School of Medicine, and BeeKeeperAI leading the way in developing trusted AI solutions.' MSM, Icahn School of Medicine, and BeeKeeperAI are all members of CHAI and have adopted its scorecard model for algorithm developers seeking to demonstrate real-world performance to the broader market. Their shared goal is to accelerate the responsible development, validation, and market adoption of AI that improves clinical decision-making, reduces hospital readmissions, and ensures needs-based outcomes—particularly for patients with lower resource availability who face disproportionate risk from chronic heart failure. 'To bring healthcare AI to market, speed matters—but so does trust,' said Dr. Michael Blum, MD, Co-founder and CEO of BeeKeeperAI. 'With EscrowAI, Icahn School of Medicine and Morehouse School of Medicine can enable AI developers to securely test their models on high-value, real-world data in days—not months—while preserving patient privacy and model IP. This is how we unlock faster, scalable, and equitable innovation in healthcare.' The curated datasets, based on shared specifications, include clinical, demographic, and social determinants of health data—offering a rare opportunity to assess algorithm performance across institutions serving predominantly resource-limited populations. 'Morehouse School of Medicine is committed to ensuring all patients have the opportunity to achieve optimal outcomes from treatment for chronic heart failure,' said Muhammed Y. Idris, PhD, Assistant Professor, Medicine and Co-Director, Center for the Validation of Digital Health Technologies and Clinical Algorithms at Morehouse School of Medicine. 'By enabling AI developers to securely compute on our data, we're creating the foundation for algorithms that can reduce readmissions and mortality for those most at risk.' 'AI has the potential to transform clinical care delivery, but only if models are proven to be accurate, safe, and effective in real-world and diverse settings,' said Tanvir Kahlon, MD, MBA, Assistant Professor, Advanced Heart Failure and Transplant, Interventional Cardiology at Icahn School of Medicine at Mount Sinai. 'Our work with BeeKeeperAI and Morehouse makes that assurance possible—without compromising privacy or integrity.' Accelerating Trustworthy & Responsible AI with Privacy-Enhancing Technology BeeKeeperAI's EscrowAI platform allows AI model testing inside a data steward's secure environment using Trusted Execution Environments (TEEs) with confidential computing—ensuring data privacy, regulatory compliance, and protection of IP throughout the process. As a recently certified CHAI Assurance Service Provider, BeeKeeperAI meets the highest standards for ethical and secure AI validation. EscrowAI replaces lengthy data access and contracting delays with push-button, compliant testing workflows —compressing timelines and accelerating time-to-value for algorithm developers. Developers can test and prove model performance on real-world, regulated data in a SOC 2-compliant environment aligned with CHAI's data integrity and scorecard framework. The resulting performance reports are immutable, transparent, and reproducible—creating a fast, scalable path to market evaluation and adoption. CHAI Assurance: A Market-Based Model for Responsible AI This collaboration reflects a broader shift in healthcare AI—from evaluations too often based on marketing presentations to more evidence-based, transparent assurance. CHAI's conflict-of-interest and ethics policies ensure independent oversight, while BeeKeeperAI's infrastructure delivers privacy-protected reproducibility, regulatory-grade audit trails, and speed-to-deployment. Together, they support faster validation and value-based procurement for AI solutions that work, including in populations that need them most. As part of this initiative, Icahn School of Medicine and Morehouse School of Medicine will be publishing data catalogs, enabling independent AI testing and validation to support the new benchmark for healthcare AI transparency and efficiency. About BeeKeeperAI BeeKeeperAI is the pioneer in privacy-enhancing technologies, integrating Trusted Execution Environments with confidential computing to accelerate AI validation and deployment in regulated sectors, including healthcare and government. BeeKeeperAI enables real-world data to be used safely and securely, without ever exposing it—empowering institutions to bring trusted AI to market faster. Learn more at Icahn School of Medicine at Mount Sinai is an investor in BeeKeeperAI.
Yahoo
03-04-2025
- Politics
- Yahoo
Morehouse School of Medicine names building after former State Rep. Calvin Smyre
The longest-serving member of the Georgia House of Representatives has received a new honor for his decades of service. On Thursday, Morehouse School of Medicine dedicated a new building to former State Rep. Calvin Smyre, who has supported the institution since it started. Channel 2′s Karyn Greer was there as Governor Brian Kemp and Atlanta Mayor Andre Dickens cut the ribbon for the dedication of the Calvin Smyre Education Conference Center. 'Having a building that houses our future generation of doctors named after you is a wild moment,' Smyre said. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Smyre was 26 in 1974 when he was first elected to the Georgia State House where he served for 48 years before stepping down in 2023 at the age of 74. Now decades later, Smyre's contributions to the state is literally being etched in stone. 'To be involved in this process and to have been involved with the Morehouse School of Medicine since 1975, and it's 2025, that's 50 years. And to see these young students, you know, it just brings joy to you,' he said. Gov. Kemp said he's proud to have closely worked with Smyre for so many years. 'Calvin Smyre is just a great American, a great Georgian, great member of the House of Representatives and somebody that I've worked very closely with,' the governor said. 'And I think you saw that, saw the affection he had for our past governors and how closely he worked with them and appreciated them.' TRENDING STORIES: Young Thug's attorney says rapper didn't violate his probation over social media repost Dow drops nearly 1,680 in biggest wipeout since 2020 as fears of fallout from tariffs shake markets 'Speedy Gonzalez' arrested in string of Walmart thefts First Lady Marty Kemp says she has a special relationship with Smyre, who served in the State House with her father, Bob Argo. 'When Brian did his first day at the state, they let me sit in dad's seat, and I turned around, and [Smyre] was like, 'That's Mr. Bob's seat.' And it just meant so much,' she said. Building the Calvin Smyre Education Conference Center took three years and $14.5 million. Morehouse School of Medicine President Dr. Valerie Montgomery-Rice says she proud of the work that went into it, and to get to recognize Smyre. 'This is a special day, this is a three-year dream come true. And it is the culmination of really acknowledging the work of someone who's been our champion,' Dr. Montgomery-Rice said. Smyre is still a board member emeritus at the school and continues to tout the work they've done to legislators and community leaders. [SIGN UP: WSB-TV Daily Headlines Newsletter]
CNN
27-02-2025
- Health
- CNN
Alzheimer's disease research: How Dr. Solomon Carter Fuller contributed
Alzheimer's disease is increasingly widespread, affecting more than 55 million people worldwide — a figure that's expected to nearly triple by 2050. Despite the disease's prevalence, few know the history of research on Alzheimer's and the role played by an important yet long-overlooked figure: Dr. Solomon Carter Fuller, the first Black psychiatrist and neurologist in the United States. Fuller's work 'not only advanced the understanding of Alzheimer's disease, but also exemplified how diverse backgrounds and perspectives in medical research can drive scientific progress and improve patient care across different communities,' said Dr. Chantale Branson, associate professor of neurology at the Morehouse School of Medicine in Atlanta. Fuller was born on August 11, 1872, in Monrovia, Liberia, to Solomon Fuller, a coffee planter and local government official, and Anna Ursula James. His paternal grandparents were formerly enslaved in Virginia before they bought their freedom and then immigrated to Liberia in 1852. Related video Woman claims Alzheimer's symptoms were reversed after five years There, the couple helped establish a settlement for other freed African or African American people. His maternal grandparents were medical missionaries in Liberia, helping to ignite Fuller's interest in medicine, Branson said. That curiosity led a 17-year-old Fuller to move to the US, where he attended Livingstone College in North Carolina. He went on to study medicine at Long Island College Hospital in Brooklyn and earn a medical degree from Boston University in 1897, according to the university. Exploring Boston a few years earlier, Branson said, Fuller had walked into the institution and asked administrators to accept him as a medical student. During a time of segregation that was merely 34 years since the Emancipation Proclamation but still nearly 70 before the Civil Rights Act, Fuller's prevailing and obtaining his medical doctorate is a remarkable achievement. But Fuller 'was really one of those people who didn't accept 'no' for an answer,' Branson recalled learning from a conversation she had with one of his family members a few years ago. READ MORE: What Robin Williams' widow wants you to know about the future of Lewy body dementia Boston University was also the first US university to admit female students into the medical college, so it may have been more inclined than other institutions to be open to minorities at that time in history. Highlighting the complexity of Alzheimer's disease Fuller then became a neuropathologist at Westborough State Hospital, a Massachusetts-based psychiatric hospital, where he performed autopsies throughout a two-year internship. His expertise earned him a Boston University faculty position as a full-time instructor in pathology in 1899, according to the university. Desiring greater knowledge, Fuller connected with Bellevue Hospital in New York state, which had a pathology lab that was the envy of others in the field, said Dr. Tia Powell, clinical professor in the department of epidemiology and population health at Albert Einstein College of Medicine in New York City. A colleague advised Fuller that to further excel, he needed to go to Europe, where the level of science and medical education outperformed that of the US, added Powell, author of 'Dementia Reimagined: Building a Life of Joy and Dignity from Beginning to End.' In 1903, German researcher and pathologist Dr. Alois Alzheimer — whom the disease was eventually named after — was searching for foreign researchers who could assist him in brain research at his Royal Psychiatric Clinic lab at the Ludwig Maximilian University of Munich in Germany. Fuller was one of only five scientists Alzheimer chose. Alzheimer was interested in the normal and pathological anatomy of the brain's cerebral cortex. So he and his team, including Fuller, used advanced techniques for preserving and staining brain tissues and cells to study them under a microscope, Powell said. Multiple reports credit Fuller with the discovery of two brain abnormalities that are hallmark indicators of Alzheimer's disease: neurofibrillary tangles and amyloid plaques. The former are fibrous tangles made from the protein tau, whereas amyloid plaques are the buildup of beta amyloid, a protein that's created during normal brain activity and accumulates as we age. But Alzheimer was the first to discover and describe the tangles in 1906, following his autopsy of Auguste Deter, his former patient, experts said. At only age 51, Deter had been experiencing memory problems, disorientation and hallucinations. Alzheimer also noted that Deter's cerebral cortex was thinner than normal, and that senile plaque was also present. He pioneered the leading theory on the culprit behind Alzheimer's disease, which is that these tangles and plaques block nerve cells from communicating, eventually killing them. What Fuller did, however, was challenge this notion, Powell said. Once Fuller returned to Westborough State Hospital, he discovered there were people who had died without having shown any symptoms of dementia yet had lots of plaques and tangles in their brains. The opposite was true for other patients. Fuller argued that the plaques and tangles were therefore 'neither necessary nor sufficient for what we would call dementia,' meaning there wasn't always an easy correlation between those features and dementia, Powell said. 'It's a pretty striking observation,' Powell added. 'He's a great scientist in that he looked at the data and he spoke very honestly about what he thought it proved and didn't prove. 'And there are never enough scientists who really do that, who are willing to go against an argument put forward by their supervisors (and that there's a growing consensus around),' Powell said. 'It takes an incredibly brave and honest person who's really accurate, who's really careful about the conclusions he draws. And that, for any scientist, should be someone we see as a hero.' The discrepancies Fuller noted remain an unsettled area in the study of dementia, experts said. Knowing more about the pathology of a disease helps doctors better understand when and how to prevent, test and treat it, Branson said. Fuller was an early skeptic of the consensus on the causes of Alzheimer's disease, but his work has long been overlooked, Powell said. Research for her book 'was tempered with real sadness that as an academic psychiatrist, I had never heard of him,' she added. 'In all the seemingly endless years of my training, he never came up once. … And there are many, many more skeptics now.' In 1912, Fuller published the first comprehensive review of Alzheimer's disease, experts said. He also founded and edited a research journal, the Westborough State Hospital Papers. Fuller's legacy Fuller resigned from the hospital in 1919 then worked two associate professorships in pathology and neurology at Boston University. He remained there until 1933, when he retired after the university gave the neurology department chair position to a White man who was newly out of training and had just joined the faculty as an assistant professor, Branson said. For five years, Fuller had served as chair of the department but was never given the title, according to the university. 'Fuller was paid less than his fellow professors who were white,' a Boston University article reports. 'Fuller was unhappy, and said so: 'With the sort of work that I have done, I might have gone farther and reached a higher plane had it not been for the colour of my skin,' he wrote.' Fuller went on to treat patients with syphilis at a veterans hospital in Tuskegee, Alabama, and train Black psychiatrists to treat Black World War I veterans. He was married to the renowned sculptor Meta Vaux Warrick, and they had three children. He became blind from diabetes in 1944 and died from the disease at age 80 in 1953. The past several decades have seen Fuller's contributions recognized in some respects. In 1969, the American Psychiatric Association created the annual Solomon Carter Fuller Award, which honors a Black person 'who has pioneered in an area that has significantly improved the quality of life for black people.' The Black Psychiatrists of America established in 1974 the Solomon Carter Fuller Program for young Black psychiatrists. And in the same year, the Solomon Carter Fuller Mental Health Center opened in Boston. A middle school named after Fuller was built in 1994 in Framingham, Massachusetts, where he lived for many years. 'Diverse perspectives can challenge existing paradigms, promote creative thinking, and ultimately lead to breakthroughs that might otherwise be overlooked,' Branson said via email. 'This is crucial in ensuring that medical research addresses the needs of diverse populations and leads to equitable healthcare solutions because ultimately, it will benefit the entire scientific community.' People can lower their risk for Alzheimer's disease or other forms of dementia by ensuring they get proper exercise, nutrition, social connection, engagement in activities, and sleep, Branson said. 'Those neurofibrillary tangles or plaques are removed from the brain as people are sleeping.' Managing stress is also important, as well as addressing any issues with eyesight or hearing by wearing glasses or hearing aids, respectively, Powell said. 'None of these things are perfect, but they all seem to make a contribution to (healthy cognition in old age),' Powell said.
Yahoo
27-02-2025
- Health
- Yahoo
An unsung hero in the history of Alzheimer's disease research
Alzheimer's disease is increasingly widespread, affecting more than 55 million people worldwide — a figure that's expected to nearly triple by 2050. Despite the disease's prevalence, few know the history of research on Alzheimer's and the role played by an important yet long-overlooked figure: Dr. Solomon Carter Fuller, the first Black psychiatrist and neurologist in the United States. Fuller's work 'not only advanced the understanding of Alzheimer's disease, but also exemplified how diverse backgrounds and perspectives in medical research can drive scientific progress and improve patient care across different communities,' said Dr. Chantale Branson, associate professor of neurology at the Morehouse School of Medicine in Atlanta. Fuller was born on August 11, 1872, in Monrovia, Liberia, to Solomon Fuller, a coffee planter and local government official, and Anna Ursula James. His paternal grandparents were formerly enslaved in Virginia before they bought their freedom and then immigrated to Liberia in 1852. There, the couple helped establish a settlement for other freed African or African American people. His maternal grandparents were medical missionaries in Liberia, helping to ignite Fuller's interest in medicine, Branson said. That curiosity led a 17-year-old Fuller to move to the US, where he attended Livingstone College in North Carolina. He went on to study medicine at Long Island College Hospital in Brooklyn and earn a medical degree from Boston University in 1897, according to the university. Exploring Boston a few years earlier, Branson said, Fuller had walked into the institution and asked administrators to accept him as a medical student. During a time of segregation that was merely 34 years since the Emancipation Proclamation but still nearly 70 before the Civil Rights Act, Fuller's prevailing and obtaining his medical doctorate is a remarkable achievement. But Fuller 'was really one of those people who didn't accept 'no' for an answer,' Branson recalled learning from a conversation she had with one of his family members a few years ago. READ MORE: What Robin Williams' widow wants you to know about the future of Lewy body dementia Boston University was also the first US university to admit female students into the medical college, so it may have been more inclined than other institutions to be open to minorities at that time in history. Fuller then became a neuropathologist at Westborough State Hospital, a Massachusetts-based psychiatric hospital, where he performed autopsies throughout a two-year internship. His expertise earned him a Boston University faculty position as a full-time instructor in pathology in 1899, according to the university. Desiring greater knowledge, Fuller connected with Bellevue Hospital in New York state, which had a pathology lab that was the envy of others in the field, said Dr. Tia Powell, clinical professor in the department of epidemiology and population health at Albert Einstein College of Medicine in New York City. A colleague advised Fuller that to further excel, he needed to go to Europe, where the level of science and medical education outperformed that of the US, added Powell, author of 'Dementia Reimagined: Building a Life of Joy and Dignity from Beginning to End.' In 1903, German researcher and pathologist Dr. Alois Alzheimer — whom the disease was eventually named after — was searching for foreign researchers who could assist him in brain research at his Royal Psychiatric Clinic lab at the Ludwig Maximilian University of Munich in Germany. Fuller was one of only five scientists Alzheimer chose. Alzheimer was interested in the normal and pathological anatomy of the brain's cerebral cortex. So he and his team, including Fuller, used advanced techniques for preserving and staining brain tissues and cells to study them under a microscope, Powell said. Multiple reports credit Fuller with the discovery of two brain abnormalities that are hallmark indicators of Alzheimer's disease: neurofibrillary tangles and amyloid plaques. The former are fibrous tangles made from the protein tau, whereas amyloid plaques are the buildup of beta amyloid, a protein that's created during normal brain activity and accumulates as we age. But Alzheimer was the first to discover and describe the tangles in 1906, following his autopsy of Auguste Deter, his former patient, experts said. At only age 51, Deter had been experiencing memory problems, disorientation and hallucinations. Alzheimer also noted that Deter's cerebral cortex was thinner than normal, and that senile plaque was also present. He pioneered the leading theory on the culprit behind Alzheimer's disease, which is that these tangles and plaques block nerve cells from communicating, eventually killing them. What Fuller did, however, was challenge this notion, Powell said. Once Fuller returned to Westborough State Hospital, he discovered there were people who had died without having shown any symptoms of dementia yet had lots of plaques and tangles in their brains. The opposite was true for other patients. Fuller argued that the plaques and tangles were therefore 'neither necessary nor sufficient for what we would call dementia,' meaning there wasn't always an easy correlation between those features and dementia, Powell said. 'It's a pretty striking observation,' Powell added. 'He's a great scientist in that he looked at the data and he spoke very honestly about what he thought it proved and didn't prove. 'And there are never enough scientists who really do that, who are willing to go against an argument put forward by their supervisors (and that there's a growing consensus around),' Powell said. 'It takes an incredibly brave and honest person who's really accurate, who's really careful about the conclusions he draws. And that, for any scientist, should be someone we see as a hero.' The discrepancies Fuller noted remain an unsettled area in the study of dementia, experts said. Knowing more about the pathology of a disease helps doctors better understand when and how to prevent, test and treat it, Branson said. Fuller was an early skeptic of the consensus on the causes of Alzheimer's disease, but his work has long been overlooked, Powell said. Research for her book 'was tempered with real sadness that as an academic psychiatrist, I had never heard of him,' she added. 'In all the seemingly endless years of my training, he never came up once. … And there are many, many more skeptics now.' In 1912, Fuller published the first comprehensive review of Alzheimer's disease, experts said. He also founded and edited a research journal, the Westborough State Hospital Papers. Fuller resigned from the hospital in 1919 then worked two associate professorships in pathology and neurology at Boston University. He remained there until 1933, when he retired after the university gave the neurology department chair position to a White man who was newly out of training and had just joined the faculty as an assistant professor, Branson said. For five years, Fuller had served as chair of the department but was never given the title, according to the university. 'Fuller was paid less than his fellow professors who were white,' a Boston University article reports. 'Fuller was unhappy, and said so: 'With the sort of work that I have done, I might have gone farther and reached a higher plane had it not been for the colour of my skin,' he wrote.' Fuller went on to treat patients with syphilis at a veterans hospital in Tuskegee, Alabama, and train Black psychiatrists to treat Black World War I veterans. He was married to the renowned sculptor Meta Vaux Warrick, and they had three children. He became blind from diabetes in 1944 and died from the disease at age 80 in 1953. The past several decades have seen Fuller's contributions recognized in some respects. In 1969, the American Psychiatric Association created the annual Solomon Carter Fuller Award, which honors a Black person 'who has pioneered in an area that has significantly improved the quality of life for black people.' The Black Psychiatrists of America established in 1974 the Solomon Carter Fuller Program for young Black psychiatrists. And in the same year, the Solomon Carter Fuller Mental Health Center opened in Boston. A middle school named after Fuller was built in 1994 in Framingham, Massachusetts, where he lived for many years. 'Diverse perspectives can challenge existing paradigms, promote creative thinking, and ultimately lead to breakthroughs that might otherwise be overlooked,' Branson said via email. 'This is crucial in ensuring that medical research addresses the needs of diverse populations and leads to equitable healthcare solutions because ultimately, it will benefit the entire scientific community.' People can lower their risk for Alzheimer's disease or other forms of dementia by ensuring they get proper exercise, nutrition, social connection, engagement in activities, and sleep, Branson said. 'Those neurofibrillary tangles or plaques are removed from the brain as people are sleeping.' Managing stress is also important, as well as addressing any issues with eyesight or hearing by wearing glasses or hearing aids, respectively, Powell said. 'None of these things are perfect, but they all seem to make a contribution to (healthy cognition in old age),' Powell said.
CNN
27-02-2025
- Health
- CNN
Alzheimer's disease research: How Dr. Solomon Carter Fuller contributed
Alzheimer's disease is increasingly widespread, affecting more than 55 million people worldwide — a figure that's expected to nearly triple by 2050. Despite the disease's prevalence, few know the history of research on Alzheimer's and the role played by an important yet long-overlooked figure: Dr. Solomon Carter Fuller, the first Black psychiatrist and neurologist in the United States. Fuller's work 'not only advanced the understanding of Alzheimer's disease, but also exemplified how diverse backgrounds and perspectives in medical research can drive scientific progress and improve patient care across different communities,' said Dr. Chantale Branson, associate professor of neurology at the Morehouse School of Medicine in Atlanta. Fuller was born on August 11, 1872, in Monrovia, Liberia, to Solomon Fuller, a coffee planter and local government official, and Anna Ursula James. His paternal grandparents were formerly enslaved in Virginia before they bought their freedom and then immigrated to Liberia in 1852. Related video Woman claims Alzheimer's symptoms were reversed after five years There, the couple helped establish a settlement for other freed African or African American people. His maternal grandparents were medical missionaries in Liberia, helping to ignite Fuller's interest in medicine, Branson said. That curiosity led a 17-year-old Fuller to move to the US, where he attended Livingstone College in North Carolina. He went on to study medicine at Long Island College Hospital in Brooklyn and earn a medical degree from Boston University in 1897, according to the university. Exploring Boston a few years earlier, Branson said, Fuller had walked into the institution and asked administrators to accept him as a medical student. During a time of segregation that was merely 34 years since the Emancipation Proclamation but still nearly 70 before the Civil Rights Act, Fuller's prevailing and obtaining his medical doctorate is a remarkable achievement. But Fuller 'was really one of those people who didn't accept 'no' for an answer,' Branson recalled learning from a conversation she had with one of his family members a few years ago. READ MORE: What Robin Williams' widow wants you to know about the future of Lewy body dementia Boston University was also the first US university to admit female students into the medical college, so it may have been more inclined than other institutions to be open to minorities at that time in history. Highlighting the complexity of Alzheimer's disease Fuller then became a neuropathologist at Westborough State Hospital, a Massachusetts-based psychiatric hospital, where he performed autopsies throughout a two-year internship. His expertise earned him a Boston University faculty position as a full-time instructor in pathology in 1899, according to the university. Desiring greater knowledge, Fuller connected with Bellevue Hospital in New York state, which had a pathology lab that was the envy of others in the field, said Dr. Tia Powell, clinical professor in the department of epidemiology and population health at Albert Einstein College of Medicine in New York City. A colleague advised Fuller that to further excel, he needed to go to Europe, where the level of science and medical education outperformed that of the US, added Powell, author of 'Dementia Reimagined: Building a Life of Joy and Dignity from Beginning to End.' In 1903, German researcher and pathologist Dr. Alois Alzheimer — whom the disease was eventually named after — was searching for foreign researchers who could assist him in brain research at his Royal Psychiatric Clinic lab at the Ludwig Maximilian University of Munich in Germany. Fuller was one of only five scientists Alzheimer chose. Alzheimer was interested in the normal and pathological anatomy of the brain's cerebral cortex. So he and his team, including Fuller, used advanced techniques for preserving and staining brain tissues and cells to study them under a microscope, Powell said. Multiple reports credit Fuller with the discovery of two brain abnormalities that are hallmark indicators of Alzheimer's disease: neurofibrillary tangles and amyloid plaques. The former are fibrous tangles made from the protein tau, whereas amyloid plaques are the buildup of beta amyloid, a protein that's created during normal brain activity and accumulates as we age. But Alzheimer was the first to discover and describe the tangles in 1906, following his autopsy of Auguste Deter, his former patient, experts said. At only age 51, Deter had been experiencing memory problems, disorientation and hallucinations. Alzheimer also noted that Deter's cerebral cortex was thinner than normal, and that senile plaque was also present. He pioneered the leading theory on the culprit behind Alzheimer's disease, which is that these tangles and plaques block nerve cells from communicating, eventually killing them. What Fuller did, however, was challenge this notion, Powell said. Once Fuller returned to Westborough State Hospital, he discovered there were people who had died without having shown any symptoms of dementia yet had lots of plaques and tangles in their brains. The opposite was true for other patients. Fuller argued that the plaques and tangles were therefore 'neither necessary nor sufficient for what we would call dementia,' meaning there wasn't always an easy correlation between those features and dementia, Powell said. 'It's a pretty striking observation,' Powell added. 'He's a great scientist in that he looked at the data and he spoke very honestly about what he thought it proved and didn't prove. 'And there are never enough scientists who really do that, who are willing to go against an argument put forward by their supervisors (and that there's a growing consensus around),' Powell said. 'It takes an incredibly brave and honest person who's really accurate, who's really careful about the conclusions he draws. And that, for any scientist, should be someone we see as a hero.' The discrepancies Fuller noted remain an unsettled area in the study of dementia, experts said. Knowing more about the pathology of a disease helps doctors better understand when and how to prevent, test and treat it, Branson said. Fuller was an early skeptic of the consensus on the causes of Alzheimer's disease, but his work has long been overlooked, Powell said. Research for her book 'was tempered with real sadness that as an academic psychiatrist, I had never heard of him,' she added. 'In all the seemingly endless years of my training, he never came up once. … And there are many, many more skeptics now.' In 1912, Fuller published the first comprehensive review of Alzheimer's disease, experts said. He also founded and edited a research journal, the Westborough State Hospital Papers. Fuller's legacy Fuller resigned from the hospital in 1919 then worked two associate professorships in pathology and neurology at Boston University. He remained there until 1933, when he retired after the university gave the neurology department chair position to a White man who was newly out of training and had just joined the faculty as an assistant professor, Branson said. For five years, Fuller had served as chair of the department but was never given the title, according to the university. 'Fuller was paid less than his fellow professors who were white,' a Boston University article reports. 'Fuller was unhappy, and said so: 'With the sort of work that I have done, I might have gone farther and reached a higher plane had it not been for the colour of my skin,' he wrote.' Fuller went on to treat patients with syphilis at a veterans hospital in Tuskegee, Alabama, and train Black psychiatrists to treat Black World War I veterans. He was married to the renowned sculptor Meta Vaux Warrick, and they had three children. He became blind from diabetes in 1944 and died from the disease at age 80 in 1953. The past several decades have seen Fuller's contributions recognized in some respects. In 1969, the American Psychiatric Association created the annual Solomon Carter Fuller Award, which honors a Black person 'who has pioneered in an area that has significantly improved the quality of life for black people.' The Black Psychiatrists of America established in 1974 the Solomon Carter Fuller Program for young Black psychiatrists. And in the same year, the Solomon Carter Fuller Mental Health Center opened in Boston. A middle school named after Fuller was built in 1994 in Framingham, Massachusetts, where he lived for many years. 'Diverse perspectives can challenge existing paradigms, promote creative thinking, and ultimately lead to breakthroughs that might otherwise be overlooked,' Branson said via email. 'This is crucial in ensuring that medical research addresses the needs of diverse populations and leads to equitable healthcare solutions because ultimately, it will benefit the entire scientific community.' People can lower their risk for Alzheimer's disease or other forms of dementia by ensuring they get proper exercise, nutrition, social connection, engagement in activities, and sleep, Branson said. 'Those neurofibrillary tangles or plaques are removed from the brain as people are sleeping.' Managing stress is also important, as well as addressing any issues with eyesight or hearing by wearing glasses or hearing aids, respectively, Powell said. 'None of these things are perfect, but they all seem to make a contribution to (healthy cognition in old age),' Powell said.
